Novel Btk Inhibitor Heads to Phase III Trials in Chronic Lymphocytic Leukemia

1 Views
administrator
administrator
07/08/23

An experimental oral drug given once a day is drawing responses from about 70% of patients with relapsed chronic lymphocytic leukemia. Dr. Susan O'Brien explains why investigators are excited about PCI-32765 in an interview at the annual meeting of the American Society of Hematology

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next